Suppr超能文献

评估稳定型发热性中性粒细胞减少症风险分层系统的临床指标在妇科肿瘤患者发热性中性粒细胞减少症管理中的应用。

Evaluation of the clinical Index of Stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients.

作者信息

Monuszko Karen A, Albright Benjamin, Katherine Montes De Oca Mary, Thao Thi Nguyen Nguyen, Havrilesky Laura J, Davidson Brittany A

机构信息

Duke University School of Medicine, Durham, NC, 27710, United States.

Division of Gynecologic Oncology, Duke Cancer Institute, Durham, NC, 27710, United States.

出版信息

Gynecol Oncol Rep. 2021 Aug 27;37:100853. doi: 10.1016/j.gore.2021.100853. eCollection 2021 Aug.

Abstract

OBJECTIVE

Scoring systems have been developed to identify low risk patients with febrile neutropenia (FN) who may be candidates for outpatient management. We sought to validate the predictive accuracy of the Clinical Index of Stable Febrile Neutropenia (CISNE) score alone and in conjunction with alternative scoring systems for risk of complications among gynecologic oncology patients.

METHODS

We conducted a single institution retrospective cohort study of patients admitted to an academic gynecologic oncology service for FN. We examined the performance characteristics (sensitivity, specificity, positive and negative predictive value) of three scoring systems (Multinational Association of Supportive Care in Cancer (MASCC), CISNE cut-off 1 (Low risk = 0), CISNE cut-off 2 (Low risk = <3)), and the combination of MASCC and CISNE to predict complications: inpatient death, ICU admission, hypotension, respiratory/renal failure, mental status change, cardiac failure, bleeding, and arrhythmia.

RESULTS

Fifty patients were identified for study inclusion. No low-risk CISNE patients died during hospitalization. Fewer CISNE low-risk patients experienced complications compared to high-risk patients, regardless of cut-off. Sensitivity, specificity, positive and negative predictive values of the scoring systems were: CISNE 1-37.1%, 86.7%, 86.7%, 37.1%; CISNE 2-85.7%, 46.7%, 78.9%, 58.3%; MASCC-82.9%, 66.7%, 85.3%, 62.5%; MASCC + CISNE 1-37.1%, 93.3%, 92.9%, 38.9%; MASCC + CISNE 2-80%, 73.3%, 87.5%, 61.1%.

CONCLUSIONS

The CISNE scoring system is an appropriate tool for the identification of patients with gynecologic cancers and FN who may benefit from close outpatient management. CISNE cut-off 2 performed comparably to the MASCC, but CISNE cut-off 1 had a higher specificity and positive predictive value.

摘要

目的

已开发出评分系统来识别发热性中性粒细胞减少症(FN)的低风险患者,这些患者可能适合门诊治疗。我们试图验证稳定型发热性中性粒细胞减少症临床指数(CISNE)评分单独以及与其他评分系统联合使用时,对妇科肿瘤患者并发症风险的预测准确性。

方法

我们对一家学术性妇科肿瘤科室收治的FN患者进行了单机构回顾性队列研究。我们检查了三种评分系统(癌症支持治疗多国协会(MASCC)、CISNE临界值1(低风险=0)、CISNE临界值2(低风险<3))以及MASCC和CISNE联合使用时预测并发症的性能特征(敏感性、特异性、阳性预测值和阴性预测值),这些并发症包括:住院死亡、入住重症监护病房(ICU)、低血压、呼吸/肾衰竭、精神状态改变、心力衰竭、出血和心律失常。

结果

确定了50名患者纳入研究。CISNE低风险患者在住院期间均未死亡。无论临界值如何,与高风险患者相比,CISNE低风险患者发生并发症的情况较少。各评分系统的敏感性、特异性、阳性预测值和阴性预测值分别为:CISNE 1 - 37.1%、86.7%、86.7%、37.1%;CISNE 2 - 85.7%、46.7%、78.9%、58.3%;MASCC - 82.9%、66.7%、85.3%、62.5%;MASCC + CISNE 1 - 37.1%、93.3%、92.9%、38.9%;MASCC + CISNE 2 - 80%、73.3%、87.5%、61.1%。

结论

CISNE评分系统是识别可能从密切门诊治疗中获益的妇科癌症和FN患者的合适工具。CISNE临界值2的表现与MASCC相当,但CISNE临界值1具有更高的特异性和阳性预测值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fea/8414105/0f61dc4f7a30/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验